YTHDF2 and non-small cell lung carcinoma: Notably, exosomal-FTO facilitated ABCC10 of recipient cells via FTO/YTHDF2/ABCC10 axis, eventually leading to gefitinib resistance in non–small cell lung cancer (NSCLC) [47].